The Food and Drug Administration tipped its hand about enforcement areas it would prioritize in a revised draft guidance for the homeopathic drug sector when it warned manufacturers and a marketer in May about ophthalmic product quality control and labeling problems.
The priority enforcement areas listed in the draft guidance published 24 October also notes delivery formats other than oral and topical
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?